STOCK TITAN

VolitionRX Limited - VNRX STOCK NEWS

Welcome to our dedicated page for VolitionRX news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on VolitionRX stock.

VolitionRx Limited (VNRX) is a U.S.-based epigenetics company at the forefront of developing non-invasive blood tests for early detection and monitoring of life-altering diseases, including various cancers. By leveraging their proprietary Nucleosomics™ platform, VolitionRx is pioneering diagnostic tests that identify and measure nucleosomes in the bloodstream, indicating the presence of disease.

The company's goal is to make these blood tests as commonplace and straightforward as current diabetic and cholesterol tests. VolitionRx operates through subsidiaries, with its primary research and development activities based in Belgium. The company also has offices in the U.S., London, and Singapore, focusing on bringing revolutionary diagnostic products to market across Europe, the U.S., and globally.

VolitionRx's innovative product portfolio includes the Nu.Q® NETs test and the Nu.Q® Vet Cancer Test. The company has recently expanded into veterinary diagnostics with the Nu.Q® Vet Cancer Test, now available in Japan through a partnership with Fujifilm Vet Systems and in the U.S. and Europe through Antech Diagnostics. This expansion aims to provide veterinarians with simple, cost-effective tools for early cancer detection in dogs.

In 2023, VolitionRx achieved several milestones, including significant partnerships and the commercialization of its veterinary products. The company also made strides in its human diagnostics pipeline, with plans to advance its regulatory pathway with the U.S. FDA and large-scale clinical studies scheduled for publication.

VolitionRx remains focused on advancing the science of epigenetics to improve patient outcomes. The company aims to achieve cash flow neutrality by 2025 through a mix of revenue growth, milestone payments from licensing agreements, and cost reduction measures.

For more information, visit www.volitionrx.com, or follow them on Twitter, LinkedIn, and Facebook.

Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) has been invited to join a government-backed study in France to assess blood biomarkers for early lung cancer detection, partnering with Hospices Civils de Lyon. The ILYAD study aims to evaluate Volition's Nu.Q® test in detecting lung cancer, involving over 400 subjects over the next year. Chief Commercial Officer Gael Forterre emphasized the critical need for effective lung cancer screening globally. Volition specializes in developing cost-effective blood tests using its innovative Nucleosomics™ technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.55%
Tags
conferences
-
Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) has launched its Nu.Q® Vet Cancer Screening Test across the U.S. and plans to expand into Europe via Heska Corporation (NASDAQ: HSKA). The test offers an accurate, affordable, and non-invasive method for early cancer detection in dogs. With approximately 84 million pet dogs in the U.S., this screening can enhance health outcomes by facilitating early treatment. This partnership aligns with Heska's growth strategy in advanced veterinary diagnostics, following a $28 million licensing agreement with Volition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.15%
Tags
none
-
Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) has signed a global supply agreement with a leading pet healthcare provider to supply the Nu.Q® Vet Cancer Test via its laboratory network. This test aims at early cancer detection in pets, particularly senior dogs, providing significant market potential given the 84 million pet dogs in the U.S. Dr. Tom Butera emphasized that this agreement helps commercialize their technology in animal healthcare. Clinical studies indicate the test can detect 76% of systemic cancers with high specificity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.76%
Tags
none
Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO) announced the signing of a patent assignment from CLS Therapeutics as part of a collaboration with CLS and VolitionRx (NYSE AMERICAN: VNRX) to develop NETs-targeted adoptive cell therapies for cancer. In exchange for the patent, Xenetic will issue 850,000 shares to CLS. This collaboration aims to combine Volition's Nu.Q technology and Xenetic's DNase-Armored CAR T platform, targeting various solid tumors where current therapies are ineffective. The partnership will also share proceeds from any resulting commercial products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.63%
Tags
none
-
Rhea-AI Summary

VolitionRx Limited (NYSE: VNRX) appointed Mickie Henshall to its board of directors effective August 15, 2022. Henshall brings over 20 years of marketing experience in the IVD and life science industries, previously holding key positions at Illumina and REALM IDx. The board believes her expertise will support Volition's commercialization efforts, particularly regarding its Nu.Q® technology. Henshall noted the company's potential to revolutionize diagnostics for life-altering diseases. Volition is focused on developing cost-effective blood tests for monitoring diseases, including cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
management
-
Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) announced its second-quarter financial results for the period ending June 30, 2022. The company reported cash and cash equivalents of approximately $16.7 million, down from $20.6 million at year-end 2021. However, they secured $6.4 million via a public offering post-quarter and received $1.5 million in non-dilutive funding. Volition has made strides with the CE Mark for its Nu.Q® NETs test in Europe and is expanding clinical studies in the U.S. with MD Anderson and Diagnostic Oncology CRO LLC, aiming for FDA clearance in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) announced a sponsored research agreement with The University of Texas MD Anderson Cancer Center to study neutrophil extracellular traps (NETs) in cancer patients with sepsis. Led by Professor Jyotika Sharma, the study will utilize Volition's Nu.Q® NETs test, recently CE marked for NETosis evaluation. This research targets the critical early identification of sepsis risk in cancer patients, aiming to improve outcomes. High NET levels are linked to severe reactions and organ failure, emphasizing the test's potential in clinical settings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
-
Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) has appointed Diagnostic Oncology CRO, LLC (DXOCRO) to lead development and clinical validation studies for its Nu.Q® product range in the U.S. The collaboration aims to establish clinical utility for its tests related to sepsis and cancer, ultimately seeking FDA clearance. DXOCRO brings expertise in commercialization and regulatory affairs to Volition, enhancing its strategy for U.S. market entry. This partnership supports Volition's objective to demonstrate the potential of its Nucleosomics™ technology in improving patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) announced a $1.5 million non-dilutive funding from Namur Invest Capital Risk in Belgium. This funding will support an early access program for Volition's Nu.Q® product portfolio across the EU, UK, and USA. COO Gaetan Michel expressed excitement for advancing Nucleosomics™ technology and engaging industry leaders. The funding is part of over $14 million in grants from Walloon Region since 2016, and the loan will bear a 6% interest rate, repayable over four years, maturing on July 31, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
none
Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) announced the closing of its public offering of 3,450,000 shares at $2.00 each, raising gross proceeds of $6.9 million. The proceeds will be allocated for research, product development, clinical studies, and potential strategic acquisitions. The offering was facilitated by Newbridge Securities Corporation and is part of a previously filed shelf registration. The company focuses on developing blood tests to diagnose serious diseases using its Nucleosomics™ platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags

FAQ

What is the current stock price of VolitionRX (VNRX)?

The current stock price of VolitionRX (VNRX) is $0.6759 as of December 20, 2024.

What is the market cap of VolitionRX (VNRX)?

The market cap of VolitionRX (VNRX) is approximately 56.5M.

What does VolitionRx Limited do?

VolitionRx Limited develops non-invasive blood tests for early detection and monitoring of diseases, including cancers, using their proprietary Nucleosomics™ platform.

Where is VolitionRx Limited based?

VolitionRx Limited is a U.S.-based company with research and development activities centered in Belgium. They also have offices in the U.S., London, and Singapore.

What is the Nu.Q® Vet Cancer Test?

The Nu.Q® Vet Cancer Test is a blood test developed by VolitionRx to aid early cancer detection in dogs. It's available through partnerships with Fujifilm Vet Systems in Japan and Antech Diagnostics in the U.S. and Europe.

What are VolitionRx's recent achievements?

In 2023, VolitionRx expanded its partnership network, commercialized its veterinary products, and advanced its human diagnostics pipeline with plans for regulatory submissions and new clinical studies.

What is the Nucleosomics™ platform?

Nucleosomics™ is VolitionRx's proprietary technology for identifying and measuring nucleosomes in the bloodstream, which can indicate the presence of disease.

How is VolitionRx planning to achieve cash flow neutrality by 2025?

VolitionRx aims for cash flow neutrality by 2025 through revenue growth, milestone payments from licensing agreements, and cost reduction measures.

How can I get more information about VolitionRx?

Visit their website at www.volitionrx.com or follow them on Twitter, LinkedIn, and Facebook for the latest updates and information.

What diseases does VolitionRx target with its tests?

VolitionRx targets a range of diseases, including various cancers and diseases associated with NETosis, such as sepsis and COVID-19.

What is the significance of VolitionRx's partnership with Fujifilm Vet Systems?

The partnership allows Fujifilm Vet Systems to sell and perform cancer screening services for dogs using the Nu.Q® Vet Cancer Test throughout Japan, enhancing early cancer detection.

What upcoming milestones does VolitionRx expect?

VolitionRx anticipates publishing new data for their Nu.Q® NETs and Capture-PCR™ technologies and advancing their regulatory pathways in 2024.

VolitionRX Limited

NYSE:VNRX

VNRX Rankings

VNRX Stock Data

56.49M
70.00M
22.82%
19.11%
0.48%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States of America
HENDERSON